Table 5. Metabolic and cardiovascular profile according to the presence of metabolic syndrome and/or new onset diabetes after transplant.
| None N = 271 | MS N = 230 | NODAT N = 6 | MS/NODATa N = 84 | p-value | |
|---|---|---|---|---|---|
| FBGb at last follow-up, mg/dL (SD) | 89.2 (8.3) | 98.5 (12.4) | 108.7 (21.7) | 119.9 (29.3) | <0.001 |
| BMI at last follow-up, kg/m2 (SD) | 26.6 (5.2) | 32.7 (6.8) | 27.5 (8.1) | 34.1 (6.5) | <0.001 |
| Change in BMI, kg/m2 (SD) | 1.8 (3.3) | 4.0 (4.1) | 0.7 (3.3) | 3.4 (4.1) | <0.001 |
| Total cholesterol, mg/dL (SD) | 192.8 (42.0) | 183.4 (38.0) | 155.0 (9.9) | 188.0 (49.4) | 0.02 |
| Triglyceride, mg/dL (SD) | 142.5 (71.4) | 225.9 (99.2) | 98.5 (33.2) | 250.4 (269.1) | <0.001 |
| HDL cholesterol, mg/dL (SD) | 59.3 (16.6) | 43.8 (12.6) | 57.2 (9.5) | 43.9 (12.2) | <0.001 |
| LDL cholesterol, mg/dL (SD) | 104.6 (34.1) | 94.7 (28.6) | 78.0 (13.9) | 99.2 (36.5) | 0.003 |
| Statins usage, yes (%) | 144 (54.1) | 165 (71.7) | 6 (100) | 68 (81.0) | <0.001 |
| Uric acid, mg/dL (SD) | 6.7 (1.7) | 7.3 (1.8) | 5.6 (2.0) | 7.2 (1.8) | <0.001 |
| Allopurinol usage, (%) | 28 (10.3) | 40 (17.4) | 0 (0) | 13 (15.5) | 0.11 |
| SBP, mmHg (SD) | 129.9 (17.4) | 133.9 (16.2) | 135.5 (17.0) | 133.9 (21.1) | 0.05 |
| DBP, mmHg (SD) | 75.2 (11.5) | 76.7 (12.2) | 69.5 (10.5) | 71.6 (12.1) | 0.005 |
| PPc, mmHg (SD) | 54.7 (14.7) | 57.1 (14.1) | 66.0 (23.3) | 62.3 (18.4) | <0.001 |
| Anti-HTN meds (SD) | 1.7 (1.1) | 2.3 (1.2) | 1.5 (1.0) | 2.5 (1.1) | <0.001 |
| RASd blocker, yes (%) | 153 (56.5) | 147 (63.9) | 4 (66.7) | 58 (69.1) | 0.13 |
| aMDRD, mL/min (SD) | 52.0 (16.4) | 49.6 (16.6) | 52.2 (9.9) | 53.0 (19.3) | 0.29 |
BMI, body mass index; HDL, high density lipoprotein.
a
Patients with both diagnosis.
b
FBG, fasting blood glucose.
c
PP, pulse pressure.
d
RAS, rein–angiotensin system.